1. Scrip
  2. >>R&D
  3. >>Clinical Trials

What GSK’s Depemokimab Will Have To Show In Chronic Rhinosinusitis

 
• By Elizabeth Cairns

Until the full data are released, it is difficult to weigh ANCHOR.

nose
• Source: Alamy

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a minor indication for GSK’s depemokimab compared with its commercial potential in asthma. Nonetheless, the market is worth contesting, and the topline Phase III hit the UK group disclosed on 14 October could enable it to carve out share from occupants including Dupixent.

Key Takeaways
  • GSK’s anti-IL-5 antibody depemokimab has succeeded in the twin ANCHOR-1 and -2 studies in chronic rhinosinusitis with nasal polyps, though only the topline hit has been revealed so far.

However, depemokimab has itself set an uneasy precedent. Its pivotal asthma trial was revealed as a success in May, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 
• By Alaric DeArment

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

More from Therapy Areas

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.